Takasu S, Wakabayashi T, Kajita Y, Hatano N, Hatano H, Usui T, Kinoshita T, Yoshida J
Department of Neurosurgery, Nagoya University School of Medicine, Japan.
No Shinkei Geka. 2000 Sep;28(9):789-94.
Six cases with recurrent or refractory primary central nervous system lymphoma were treated with a new chemotherapeutic regimen "DeVIC (dexamethasone, VP16, ifosfamide, carboplatin)". Five recurrent cases had a remission period for an average of 18 months after initial treatment, but relapse occurred. One refractory case had no response after initial treatment. Then these 6 cases were treated with 1-3 courses of DeVIC chemotherapy at intervals of 4 weeks. Two cases achieved complete remission, and 3 cases attained partial remission (response rate was 83%). One case showed no response after 1 course of DeVIC chemotherapy. However, in all cases re-relapse occurred 1-5 months after remission, and only 1 case is still alive. DeVIC chemotherapy produced a high response rate for recurrent central nervous system lymphoma, but re-relapse occurred after only a few months. The establishment of maintenance chemotherapy is required.
6例复发或难治性原发性中枢神经系统淋巴瘤患者接受了一种新的化疗方案“DeVIC（地塞米松、依托泊苷、异环磷酰胺、卡铂）”治疗。5例复发患者在初始治疗后平均缓解期为18个月，但随后复发。1例难治性患者在初始治疗后无反应。然后这6例患者每隔4周接受1 - 3个疗程的DeVIC化疗。2例达到完全缓解，3例获得部分缓解（缓解率为83%）。1例患者在1个疗程的DeVIC化疗后无反应。然而，所有病例在缓解后1 - 5个月均再次复发，仅1例仍存活。DeVIC化疗对复发性中枢神经系统淋巴瘤产生了较高的缓解率，但仅几个月后就再次复发。需要建立维持化疗。
